Equity and debt offerings as they're announced. https://www.quantisnow.com/news/offerings en-us Thu, 13 Aug 2026 04:52:36 GMT Delek Logistics Partners, LP (NYSE:DKL) ("Delek Logistics") announced today the pricing of its underwritten public offering of 4,000,000 common units representing limited partner interests in Delek Logistics at $50.00 per unit. The offering is being made pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC"). A preliminary prospectus supplement relating to the offering has also been filed with the SEC. Delek Logistics has granted the underwriters a 30-day option to purchase up to 600,000 additional common units. Delek Logistics intends to use the net proceeds from the offering (including any net proceeds from the underw https://www.quantisnow.com/insight/delek-logistics-partners-lp-announces-pricing-of-public-offering-of-6678923 https://www.quantisnow.com/insight/delek-logistics-partners-lp-announces-pricing-of-public-offering-of-6678923 Thu, 13 Aug 2026 04:27:00 GMT AbCellera Biologics Inc. (NASDAQ:ABCL) ("AbCellera") today announced the pricing of its oversubscribed underwritten public offering of 17,435,897 common shares at a price to the public of $9.75 per share and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 3,076,926 shares of its common shares at a price to the public of $9.74999 per pre-funded warrant, which represents the per share public offering price of each common share less the $0.00001 per share exercise price for each pre-funded warrant. The gross proceeds to AbCellera from the offering are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and e https://www.quantisnow.com/insight/abcellera-announces-pricing-of-oversubscribed-200-million-public-offering-of-6678922 https://www.quantisnow.com/insight/abcellera-announces-pricing-of-oversubscribed-200-million-public-offering-of-6678922 Thu, 13 Aug 2026 04:05:00 GMT ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics"), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accompanying warrants to purchase up to an aggregate of 55,555,556 shares of its common stock. The combined public offering price of each share of common stock and accompanying warrant to purchase one share is $0.99. The accompanying warrants have an exercise price of $1.10 per share, will become exercisabl https://www.quantisnow.com/insight/outlook-therapeutics-announces-pricing-of-550-million-public-offering-of-6678909 https://www.quantisnow.com/insight/outlook-therapeutics-announces-pricing-of-550-million-public-offering-of-6678909 Thu, 13 Aug 2026 01:45:00 GMT Mobilewalla Holdco, Inc. ("Mobilewalla" or the "Company"), a leading provider of consumer data and vertical agentic AI solutions, and SPACSphere Acquisition Corp. (NASDAQ:SSAC) ("SPACSphere" or "SSAC"), a publicly traded special purpose acquisition company, today announced the public filing of a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC"), containing a preliminary proxy statement and prospectus relating to their previously announced proposed business combination. A copy of the Registration Statement can be found at both the Securities and Exchange website at www.sec.gov and Mobilewalla’s website at www.mobilewall https://www.quantisnow.com/insight/mobilewalla-and-spacsphere-acquisition-corp-announce-filing-of-registration-statement-6678766 https://www.quantisnow.com/insight/mobilewalla-and-spacsphere-acquisition-corp-announce-filing-of-registration-statement-6678766 Wed, 12 Aug 2026 22:30:00 GMT PASADENA, Calif., Aug. 12, 2026 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. ("Alexandria" or the "Company") (NYSE:ARE) today announced that it has priced a public offering of $1,000,000,000 aggregate principal amount of 7.250% Series A Fixed-to-Fixed Reset Rate Junior Subordinated Notes due 2057 (the "notes"). J.P. Morgan Securities LLC, BofA Securities, Inc., Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, RBC Capital Markets, LLC, BBVA Securities Inc., Mizuho Securities USA LLC, Scotia Capital (USA) Inc., SMBC Nikko Securities America, Inc., TD Securities (USA) LLC, Truist Securities, Inc., U.S. Bancorp Investments, Inc., BNP Paribas Securities Corp. and PNC Capital Marke https://www.quantisnow.com/insight/alexandria-real-estate-equities-inc-announces-pricing-of-public-offering-6678755 https://www.quantisnow.com/insight/alexandria-real-estate-equities-inc-announces-pricing-of-public-offering-6678755 Wed, 12 Aug 2026 22:20:00 GMT BOSTON­­, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Cabot Corporation (NYSE:CBT) today announced that it priced a public offering of $350 million of 4.950% senior unsecured notes due 2029. The notes are being sold to the public at a price of 99.993% of the face amount thereof. Cabot will pay interest on the notes semiannually on February 15 and August 15 of each year, beginning February 15, 2027. The sale of the notes is expected to close on August 21, 2026, subject to the satisfaction of customary closing conditions. Cabot intends to use the net proceeds from the offering to repay its senior unsecured notes due September 2026 (the "2026 Notes") at maturity, with the remainder being used for worki https://www.quantisnow.com/insight/cabot-corporation-prices-350-million-4950-senior-notes-due-2029-6678660 https://www.quantisnow.com/insight/cabot-corporation-prices-350-million-4950-senior-notes-due-2029-6678660 Wed, 12 Aug 2026 21:35:51 GMT Revenues increased 13.8% to $15.1 million for the three months ended June 30, 2026 compared to $13.3 million for the three months ended June 30, 2025Net income increased 19.9% to $1.9 million for the three months ended June 30, 2026 compared to $1.6 million for the three months ended June 30, 2025, which included $1.0 million in non-cash stock-based compensation directly related to our 2025 bonus awardNet income per diluted share decreased 18.9% to $0.43 for the three months ended June 30, 2026 compared to $0.53 for the three months ended June 30, 2025Adjusted EBITDA increased $1.0 million to $3.4 million for the three months ended June 30, 2026 compared to $2.4 million for the three months https://www.quantisnow.com/insight/m-tron-industries-inc-reports-second-quarter-2026-results-6678416 https://www.quantisnow.com/insight/m-tron-industries-inc-reports-second-quarter-2026-results-6678416 Wed, 12 Aug 2026 20:57:00 GMT MINNEAPOLIS, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ:PARK) and affiliated dental practices ("Park Dental Partners," "we," "our," "us," or the "Company") today reported its second quarter financial results for 2026. Summary financial results are listed below and in the accompanying supplemental financial tables.                  (Unaudited, in millions, except per share data, and Doctor counts)                  Three Months EndedJune 30, Six Months EndedJune 30, 2026 2025 Change 2026 2025 ChangeRevenue$66.2  $63.0  5.1% $128.9 $122.0  5.6%Gross Margin$9.5  $11.9  (20.1%) $15.9 $21.8  (27.0%)Gross Margin percentage14.4%  18.9%   (450 bps)  12.3%  17.8%  (550 bps) https://www.quantisnow.com/insight/park-dental-partners-announces-second-quarter-2026-results-6678235 https://www.quantisnow.com/insight/park-dental-partners-announces-second-quarter-2026-results-6678235 Wed, 12 Aug 2026 20:33:00 GMT Total revenue of $1,449 million for the second quarter and $4,952 million on a TTM(1) basis.Rental Segment(2) revenue of $908 million for the second quarter, an increase of 39% year over year, and on a TTM(1) basis $3,189 million, an increase of 37% year over year.Net income of $19 million for the second quarter and net income of $62 million on a TTM(1) basis.Adjusted Net Income(4) for the second quarter of $43 million and Adjusted Net Income(4) of $103 million on a TTM(1) basis.Adjusted Core EBITDA(3) of $531 million for the second quarter and $1,911 million on a TTM(1) basis.Mature rental locations(2)(6) adjusted EBITDA margins were 55% on a TTM(1) basis.430 locations(6) with 23 new locati https://www.quantisnow.com/insight/equipmentshare-reports-second-quarter-financial-results-6678103 https://www.quantisnow.com/insight/equipmentshare-reports-second-quarter-financial-results-6678103 Wed, 12 Aug 2026 20:21:25 GMT EAST HANOVER, N.J., Aug. 12, 2026 /PRNewswire/ -- FGI Industries Ltd. (NASDAQ:FGI) ("FGI" or the "Company"), a leading global supplier of kitchen and bath products, today announced results for the second quarter 2026. SECOND QUARTER 2026 HIGHLIGHTS(As compared to the second quarter of 2025)Total revenue of $31.9 million, +2.9% y/yGross profit of $10.7 million, +22.5% y/yGross margin of 33.4%, +530 bps y/yOperating income of $1.4 million and net income attributable to shareholders of $1.3 millionAdjusted operating income of $1.4 million1Adjusted net income of $1.2 millionMANAGEMENT COMMENTARYDave Bruce, CEO of FGI, stated, "FGI https://www.quantisnow.com/insight/fgi-industries-announces-second-quarter-2026-results-6678002 https://www.quantisnow.com/insight/fgi-industries-announces-second-quarter-2026-results-6678002 Wed, 12 Aug 2026 20:15:00 GMT Nine Acquisitions Totaling $111.8 Million of Core Appalachia and Haynesville Minerals Signed Since June 10 IPO Record Production of 70.0 MMcfe/d for the Second Quarter 2026, Up 57% Year-Over-Year and 9% Compared to the First Quarter 2026 Initiates Quarterly Cash Dividend of $0.50 Per Share ($2.00 Annualized); Declares Prorated Initial Dividend of $0.11 Per Share for the Post-IPO Period WhiteHawk Minerals Corp. (NYSE:WHK) ("WhiteHawk" or the "Company") today announced the signing of $111.8 million of natural gas mineral and royalty acquisitions since the completion of its initial public offering on June 10, 2026, operating and financial results for the second quarter ended June 30, 202 https://www.quantisnow.com/insight/whitehawk-minerals-corp-announces-1118-million-of-acquisitions-second-quarter-6677984 https://www.quantisnow.com/insight/whitehawk-minerals-corp-announces-1118-million-of-acquisitions-second-quarter-6677984 Wed, 12 Aug 2026 20:15:00 GMT – Gross Merchandise Sales increased to a record $3.1 billion, up 34% year over year – – Revenue increased to a record $573.1 million, up 33% year over year – – Adjusted EBITDA increased 94% to $105.7 million; adjusted EBITDA margin up nearly 600 basis points year over year to 18% – – Increases full-year GMS outlook to reflect strong second quarter results – – Strengthened balance sheet with additional debt reduction, including a $100.0 million payment in July – StubHub Holdings, Inc. (NYSE:STUB), a leading global ticketing marketplace for live events, today reported financial results for the second quarter ended June 30, 2026. "The second quarter demonstrated strong demand for l https://www.quantisnow.com/insight/stubhub-announces-second-quarter-2026-results-6677980 https://www.quantisnow.com/insight/stubhub-announces-second-quarter-2026-results-6677980 Wed, 12 Aug 2026 20:15:00 GMT BitGo Holdings, Inc. (NYSE:BTGO) ("BitGo" or "the Company"), the digital asset infrastructure company, today reported its financial results for its second quarter ended June 30, 2026. Q2 2026 Highlights Clients on Platform, Normalized Assets on Platform, and Normalized Assets Staked increased 26%, 31%, and 36% year-over-year, respectively, reflecting continued growth in institutional adoption. Sharpened investment priorities and strengthened the operating model, expected to drive approximately $15 million of annualized cash savings. Expanded the use of AI across engineering and operations to accelerate software development, automate manual processes, and improve operating efficie https://www.quantisnow.com/insight/bitgo-announces-second-quarter-2026-financial-results-6677975 https://www.quantisnow.com/insight/bitgo-announces-second-quarter-2026-financial-results-6677975 Wed, 12 Aug 2026 20:15:00 GMT - Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program - Upfront proceeds from financing provide cash runway into the first quarter of 2027 ALISO VIEJO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update. "The second quarter marked co https://www.quantisnow.com/insight/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-6677965 https://www.quantisnow.com/insight/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-6677965 Wed, 12 Aug 2026 20:15:00 GMT NASHVILLE, Tenn., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Ryman Hospitality Properties, Inc. (NYSE:RHP) (the "Company") today announced the closing of its previously announced underwritten registered public offering of 5,865,000 shares of its common stock, par value $0.01 per share, at a price to the public of $117.00 per share (the "Offering"). The shares sold in the Offering included 765,000 shares sold following the August 11, 2026 exercise in full of the underwriters’ option to purchase additional shares of common stock, which were delivered at the time of the closing of the Offering. As a result, the Company received aggregate net proceeds from the sale of the common stock of approximately https://www.quantisnow.com/insight/ryman-hospitality-properties-inc-announces-closing-of-common-stock-offering-6677963 https://www.quantisnow.com/insight/ryman-hospitality-properties-inc-announces-closing-of-common-stock-offering-6677963 Wed, 12 Aug 2026 20:15:00 GMT Reports Q2 2026 GAAP Net Loss of $10.9 Million and First Half 2026 GAAP Net Loss of $21.1 MillionCalculates Q2 2026 Adjusted Net Loss of $7.2 Million and First Half 2026 Adjusted Net Loss of $13.4 Million (Non-GAAP)Ended Quarter with $10.1 Million in Cash and Cash Equivalents; Raised an Additional $6.0 Million in Gross Proceeds Subsequent to Quarter-End in a Warrant Inducement TransactionReceived EPA Certificate of Conformity for the 2026 Launch Edition and Ordered Bodies and Chassis for the First 40 Production Vehicles Subsequent to Quarter-EndRaised Approximately $24.6 Million in Gross Capital Year-to-Date Through Public Offering, Warrant Inducements and Equity Line of Credit CARLSBAD, Ca https://www.quantisnow.com/insight/aptera-motors-reports-second-quarter-and-first-half-2026-financial-6677943 https://www.quantisnow.com/insight/aptera-motors-reports-second-quarter-and-first-half-2026-financial-6677943 Wed, 12 Aug 2026 20:13:17 GMT HOUSTON, Aug. 12, 2026 /PRNewswire/ -- CleanCore Solutions, Inc. (NYSE:ZONE) ("CleanCore" or the "Company"), a company building the critical infrastructure that powers the AI economy, today announced the closing of its previously announced public offering (the "Offering") of 400,000,000 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 400,000,000 shares of common stock. Each share of common stock and accompanying warrant was offered at a combined public offering price of $0.25, for gross proceeds of approximately $100,000,000, before deducting placement agent discounts, commissions, and offering expenses. The pre-funded warrants have https://www.quantisnow.com/insight/cleancore-solutions-inc-nyse-american-zone-announces-closing-of-100-6677830 https://www.quantisnow.com/insight/cleancore-solutions-inc-nyse-american-zone-announces-closing-of-100-6677830 Wed, 12 Aug 2026 20:05:00 GMT U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026Commercial preparations advancing in anticipation of potential product launch for INO-3107Positive topline results reported from Phase 3 trial for VGX-3100 for the treatment of cervical dysplasia patients by ApolloBio, INOVIO's partner in ChinaPresented promising data from next-generation DNA-Encoded Monoclonal Antibody (DMAb™) and DNA-Encoded Protein (DPROT) programs at several scientific conferences Current cash, cash equivalents, and short-term https://www.quantisnow.com/insight/inovio-reports-second-quarter-2026-financial-results-and-recent-business-6677787 https://www.quantisnow.com/insight/inovio-reports-second-quarter-2026-financial-results-and-recent-business-6677787 Wed, 12 Aug 2026 20:05:00 GMT Delek Logistics Partners, LP (NYSE:DKL) ("Delek Logistics") announced today that it has commenced an underwritten public offering of $175 million of common units representing limited partner interests in Delek Logistics pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC"). A preliminary prospectus supplement relating to the offering will also be filed with the SEC. Delek Logistics intends to grant the underwriters a 30-day option to purchase up to an additional $26.25 million of common units. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be https://www.quantisnow.com/insight/delek-logistics-partners-lp-announces-proposed-public-offering-of-common-6677773 https://www.quantisnow.com/insight/delek-logistics-partners-lp-announces-proposed-public-offering-of-common-6677773 Wed, 12 Aug 2026 20:05:00 GMT Second-quarter revenue reached $7.4 million; first-half revenue increased 116% to $14.0 million, with 28 scanners shipped Strengthened capital position through a $10.0 million public offering and expanded direct U.S. commercial capabilities to accelerate adoption Reaffirms full-year 2026 revenue guidance of approximately $39 million Conference Call begins at 4:30 p.m. Eastern Time today QT Imaging Holding, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today reported financial results for the three and six months ended June 30, 2026, and provided a b https://www.quantisnow.com/insight/qt-imaging-delivers-strong-second-quarter-growth-while-building-the-6677741 https://www.quantisnow.com/insight/qt-imaging-delivers-strong-second-quarter-growth-while-building-the-6677741 Wed, 12 Aug 2026 20:05:00 GMT – ALTO-207 development expanded: an additional Phase 3 trial evaluating ALTO-207 as monotherapy in treatment-resistant depression (TRD) is now planned, alongside the ongoing potentially registrational Phase 2b trial; topline Phase 2b data on track for 2H 2027 – – Independent investigator-led study results published in Nature Medicine reinforce the dopaminergic mechanism underlying ALTO-207, demonstrating significant effects on anhedonia (Hedges' g=0.62, p=0.006) – – Approximately $100 million financing completed in July 2026; pro forma cash of approximately $338 million expected to fund planned operations through 2030 – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage bi https://www.quantisnow.com/insight/alto-neuroscience-reports-second-quarter-2026-financial-results-and-recent-6677714 https://www.quantisnow.com/insight/alto-neuroscience-reports-second-quarter-2026-financial-results-and-recent-6677714 Wed, 12 Aug 2026 20:03:00 GMT AEVEX Corp. (NYSE:AVEX) ("AEVEX" or the Company) announced results today for the three months ended June 30, 2026 ("Second Quarter 2026"). Total revenue of $201.8 million, up 99.5% from $101.1 million in Q2 2025 Net Income of $6.7 million compared to a net loss of $11.8 million in Q2 2025 Adjusted EBITDA* of $28.1 million compared to Adjusted EBITDA* of $3.6 million in Q2 2025 Announced definitive agreement to acquire BlackSea Technologies to expand AEVEX’s multi‑domain autonomous systems portfolio Outlook for Full Year 2026 Total revenue of $700.0 million to $720.0 million Adjusted EBITDA* of $105.0 million to $111.5 million * See "Non-GAAP Financial Measures" below https://www.quantisnow.com/insight/aevex-corp-announces-financial-results-for-second-quarter-2026-6677669 https://www.quantisnow.com/insight/aevex-corp-announces-financial-results-for-second-quarter-2026-6677669 Wed, 12 Aug 2026 20:01:00 GMT ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics"), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants to purchase shares of its common stock. Outlook Therapeutics also intends to grant the underwriters a 30-day option to purchase additional shares of its common stock and/or accompanying warrants in an amount up to fifteen percent (15%) of the shares of its common stock and/or accompanying warrants o https://www.quantisnow.com/insight/outlook-therapeutics-announces-proposed-public-offering-of-common-stock-and-6677661 https://www.quantisnow.com/insight/outlook-therapeutics-announces-proposed-public-offering-of-common-stock-and-6677661 Wed, 12 Aug 2026 20:01:00 GMT Company Reports Record $31.0M Net Income and $53.7M Adjusted EBITDA(8) Announcing New HAUS Agreement with Entropy, an Upcoming HIP-3 Deployer 1 Million HYPE Tokens Redeployed to Support HIP-3 & HIP-4 Markets Since June 2026 Sale of Remaining Legacy Life Sciences IP to Arctic Vision Executed in July 2026 DALLAS, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed DeFi company building on Hyperliquid, today reported results for the second quarter ending June 30, 2026. "We are pleased to report a second consecutive quarter of record Net Income", said Hyunsu Jung, CEO of Hyperion DeFi. Mr. Jung continued, " https://www.quantisnow.com/insight/hyperion-defi-reports-2q-2026-financial-results-with-another-record-6677657 https://www.quantisnow.com/insight/hyperion-defi-reports-2q-2026-financial-results-with-another-record-6677657 Wed, 12 Aug 2026 20:01:00 GMT /NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./VANCOUVER, BC, Aug. 12, 2026 /CNW/ -- SNOWLINE GOLD CORP. (TSX:SGD) (OTCQB:SNWGF) (the "Company" or "Snowline") is pleased to announce that it has completed its previously announced "bought deal" public offering of 11,902,500 common shares of the Company (the "Common Shares") at a price of C$14.50 per Common Share for aggregate gross proceeds of C$172,586,250, including the exercise in full by the underwriters of their over-allotment option (the "Offering"). Existing shareholder B2Gold Corp. (TSX:BTO) (NYSE:BTG) (NSX: B2G) participated in the Offering to maintain its 9.9% interest in the Company. "The opp https://www.quantisnow.com/insight/snowline-completes-c1726-million-bought-deal-public-offering-of-common-6677221 https://www.quantisnow.com/insight/snowline-completes-c1726-million-bought-deal-public-offering-of-common-6677221 Wed, 12 Aug 2026 12:53:00 GMT NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Adamas Trust, Inc. (NASDAQ:ADAM) (the "Company") announced today the pricing of an underwritten public offering of $90 million aggregate principal amount of its 9.600% senior notes due 2031 (the "Notes"). The Company has granted the underwriters a 30-day option to purchase up to an additional $13.5 million aggregate principal amount of the Notes to cover over-allotments. The offering is expected to close on August 14, 2026, subject to the satisfaction of customary closing conditions. The Company has applied to list the Notes on the Nasdaq Global Select Market ("Nasdaq") under the symbol "ADAMK" and, if the application is approved, expects tradin https://www.quantisnow.com/insight/adamas-trust-inc-announces-pricing-of-public-offering-of-senior-6677198 https://www.quantisnow.com/insight/adamas-trust-inc-announces-pricing-of-public-offering-of-senior-6677198 Wed, 12 Aug 2026 12:40:00 GMT Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash, cash equivalents and investments as of June 30, 2026 Webcast to be held today at 8:30 a.m. ET GAITHERSBURG, Md., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update. "We have achieved several important milestones as we continue to successfully execute our strategy, i https://www.quantisnow.com/insight/altimmune-announces-second-quarter-2026-financial-results-and-business-update-6676993 https://www.quantisnow.com/insight/altimmune-announces-second-quarter-2026-financial-results-and-business-update-6676993 Wed, 12 Aug 2026 11:30:00 GMT Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established  Data reported at AACR from triple combination therapy in 1L hepatocellular carcinoma (HCC) and late-line MSS CRC highlights muzastotug’s potential as a backbone combination treatment for multiple tumor types across all lines of therapy Initiated dosing in a global Phase 1/2 basket trial evaluating muzastotug in combination with a next-generation investigational IO agent through a clinical collaboration with Sanofi Investigator-initiated Phase 2 trial of muzastotug in neoa https://www.quantisnow.com/insight/adagene-reports-six-months-2026-financial-results-and-provides-corporate-6676989 https://www.quantisnow.com/insight/adagene-reports-six-months-2026-financial-results-and-provides-corporate-6676989 Wed, 12 Aug 2026 11:30:00 GMT – Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis access to be filed with the Food and Drug Administration (FDA) during the second half of 2026 – – FDA accepted IND for first-in-human clinical study of CTEV for CABG with Phase 2a study expected to start Q3 2026 – – Second quarter sales of Symvess® were $0.4 million in 2026 compared to $0.1 million in 2025 –    – Conference call today at 8:00 am ET – DURHAM, N.C., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, https://www.quantisnow.com/insight/humacyte-announces-second-quarter-2026-financial-results-and-provides-business-6676930 https://www.quantisnow.com/insight/humacyte-announces-second-quarter-2026-financial-results-and-provides-business-6676930 Wed, 12 Aug 2026 11:00:00 GMT NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Marex Group Limited ((‘Marex’ or the ‘Group’, NASDAQ:MRX) a diversified global financial services platform providing market access, infrastructure services and essential liquidity to clients across commodities and financial markets, today reported the Group’s preliminary unaudited financial results for the second quarter ('Q2 2026'). Ian Lowitt, Group Chief Executive Officer, stated, "We delivered record first half revenue and profitability, with Adjusted Profit Before Tax1 for the first six months of 2026 of $318.6m. We had a record second quarter with Adjusted Profit Before Tax1 of $165.9m, beating our strong performance in the first quarter https://www.quantisnow.com/insight/marex-group-limited-announces-second-quarter-2026-results-6676916 https://www.quantisnow.com/insight/marex-group-limited-announces-second-quarter-2026-results-6676916 Wed, 12 Aug 2026 11:00:00 GMT Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheetPhase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026European Commission granted orphan designation for exaluren in ADPKDCash and cash equivalents of $62.0 million as of June 30, 2026, expected to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD)ARLINGTON, Mass., Aug. 12, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a clinical-stage biopharmaceutical company develo https://www.quantisnow.com/insight/eloxx-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provides-6676789 https://www.quantisnow.com/insight/eloxx-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provides-6676789 Wed, 12 Aug 2026 10:00:00 GMT Silence Therapeutics plc ("Silence" or the "Company") , a global clinical-stage biotechnology company developing novel short interfering RNA ("siRNA") therapies, today announced that it has priced its previously announced underwritten public offering of 12,962,963 American Depositary Shares ("ADSs"), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States at a public offering price of $13.50 per ADS. In addition, Silence has granted the underwriters a 30-day option to purchase up to an additional 1,944,444 ADSs at the public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering are expected to https://www.quantisnow.com/insight/silence-therapeutics-announces-pricing-of-upsized-175-million-underwritten-public-6676761 https://www.quantisnow.com/insight/silence-therapeutics-announces-pricing-of-upsized-175-million-underwritten-public-6676761 Wed, 12 Aug 2026 03:20:00 GMT Savers Value Village, Inc. (the "Company") (NYSE:SVV), the largest for-profit thrift operator in the United States ("U.S.") and Canada for value priced pre-owned clothing, accessories and household goods, today announced the pricing and upsize of the previously announced public offering (the "Offering") of 20,000,000 shares of common stock, par value $0.000001, of the Company (the "Common Stock") offered by certain Ares Private Equity and Opportunistic Credit funds and accounts (the "Selling Stockholders") at a price to the public of $10.25 per share. As part of the Offering, the underwriters will have a 30-day option to purchase up to an additional 3,000,000 shares of Common Stock from the https://www.quantisnow.com/insight/savers-value-village-inc-announces-pricing-of-upsized-secondary-public-6676758 https://www.quantisnow.com/insight/savers-value-village-inc-announces-pricing-of-upsized-secondary-public-6676758 Wed, 12 Aug 2026 02:13:00 GMT CARMEL, Ind., Aug. 11, 2026 /PRNewswire/ -- OPENLANE, Inc. (NYSE:OPLN) ("OPENLANE") today announced the pricing of the previously-announced registered public offering of 8,000,000 shares of its common stock (the "offering") by Ignition Acquisition Holdings LP ("Ignition"), a fund advised by Apax Partners, L.P. ("Apax"). These shares represent a portion of OPENLANE's previously issued Series A Convertible Preferred Stock held by Ignition that converted into OPENLANE common stock in May 2026. The underwriter will offer the shares from time to time for sale in negotiated transactions or otherwise, at market prices prevailing at the time of sale, at prices related to such prevailing market price https://www.quantisnow.com/insight/openlane-announces-pricing-of-secondary-offering-of-common-stock-including-6676706 https://www.quantisnow.com/insight/openlane-announces-pricing-of-secondary-offering-of-common-stock-including-6676706 Wed, 12 Aug 2026 00:30:00 GMT GRAND CAYMAN, Cayman Islands, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion Therapeutics" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of 3,846,161 of the Company’s ordinary shares (or ordinary share equivalents) and series E warrants to purchase up to 3,846,161 ordinary at a combined public offering price of $0.65 per share (or per ordinary share equivalent) and accompanying warrants. The series E warrants will have an exercise price of $0.65 per share, will be exercisable immediately upon issuance and https://www.quantisnow.com/insight/silexion-therapeutics-announces-pricing-of-25-million-public-offering-6676685 https://www.quantisnow.com/insight/silexion-therapeutics-announces-pricing-of-25-million-public-offering-6676685 Wed, 12 Aug 2026 00:01:00 GMT NASHVILLE, Tenn., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Ryman Hospitality Properties, Inc. (NYSE:RHP) (the "Company") announced today that its subsidiaries, RHP Hotel Properties, LP (the "Operating Partnership") and RHP Finance Corporation (together with the Operating Partnership, the "Issuers"), successfully priced the private placement of $700 million aggregate principal amount of 6.250% senior notes due 2035 (the "Notes"). The Notes will be senior unsecured obligations of the Issuers and guaranteed by the Company and its subsidiaries that guarantee the Operating Partnership’s existing credit facility and the Issuers’ outstanding senior unsecured notes. The offering is expected to close on A https://www.quantisnow.com/insight/ryman-hospitality-properties-inc-announces-pricing-of-700-million-of-6676617 https://www.quantisnow.com/insight/ryman-hospitality-properties-inc-announces-pricing-of-700-million-of-6676617 Tue, 11 Aug 2026 22:22:00 GMT TSXV: ITR; NYSE American: ITRG www.integraresources.comVANCOUVER, BC, Aug. 11, 2026 /CNW/ -- Integra Resources Corp. ("Integra" or the "Company") (TSXV:ITR) (NYSE:ITRG) is pleased to announce financial and operating results for the three months ended June 30, 2026 (the "second quarter" or "Q2 2026"). The Company will host a conference call to discuss second quarter 2026 results on Wednesday, August 12, 2026 at 10:00 AM Eastern Time / 7:00 AM Pacific Time. (All amounts expressed in United States ("U.S.") dollars unless otherwise stated)Second Quarter 2026 Highlights:Mined 4.4 million tonnes of ore and 3.6 million tonnes of waste https://www.quantisnow.com/insight/integra-reports-second-quarter-2026-results-30-increase-in-quarterly-6676499 https://www.quantisnow.com/insight/integra-reports-second-quarter-2026-results-30-increase-in-quarterly-6676499 Tue, 11 Aug 2026 21:24:00 GMT On August 11, 2026, Ferguson Enterprises Inc. ("Ferguson") (NYSE:FERG) announced that it has priced a public offering (the "Notes Offering") of $700 million in aggregate principal amount of 4.800% senior unsecured notes due 2029 (the "2029 Notes") and $500 million in aggregate principal amount of 5.600% senior unsecured notes due 2036 (the "2036 Notes" and, collectively with the 2029 Notes, the "Notes"). The obligations of Ferguson under each series of Notes will be fully and unconditionally guaranteed (the "Guarantee") by Ferguson UK Holdings Limited, an indirect subsidiary of Ferguson. Ferguson expects that the closing of the Notes Offering will occur on August 14, 2026, subject to the sa https://www.quantisnow.com/insight/ferguson-prices-12-billion-of-senior-unsecured-notes-6676331 https://www.quantisnow.com/insight/ferguson-prices-12-billion-of-senior-unsecured-notes-6676331 Tue, 11 Aug 2026 20:55:00 GMT Savers Value Village, Inc. (the "Company") (NYSE:SVV), the largest for-profit thrift operator in the United States ("U.S.") and Canada for value priced pre-owned clothing, accessories and household goods, today announced the commencement of a proposed secondary public offering (the "Offering") of 15,000,000 shares of its common stock offered by certain Ares Private Equity and Opportunistic Credit funds and accounts (the "Selling Stockholders"). As part of the Offering, the Selling Stockholders also intend to grant the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of common stock at the public offering price, less the underwriting discount. In addition, the https://www.quantisnow.com/insight/savers-value-village-inc-announces-launch-of-secondary-public-offering-6676226 https://www.quantisnow.com/insight/savers-value-village-inc-announces-launch-of-secondary-public-offering-6676226 Tue, 11 Aug 2026 20:40:00 GMT CARMEL, Ind., Aug. 11, 2026 /PRNewswire/ -- OPENLANE, Inc. (NYSE:OPLN) ("OPENLANE"), today announced the launch of an underwritten secondary public offering of 8,000,000 shares of its common stock by Ignition Acquisition Holdings LP ("Ignition"), a fund advised by Apax Partners, L.P. ("Apax"). These shares represent a portion of OPENLANE's previously issued Series A Convertible Preferred Stock held by Ignition that converted into OPENLANE common stock in May 2026. The underwriter will offer the shares from time to time for sale in negotiated transactions or otherwise, at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices. https://www.quantisnow.com/insight/openlane-announces-secondary-offering-of-common-stock-including-concurrent-share-6676214 https://www.quantisnow.com/insight/openlane-announces-secondary-offering-of-common-stock-including-concurrent-share-6676214 Tue, 11 Aug 2026 20:37:00 GMT NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Ares Dynamic Credit Allocation Fund, Inc. ("ARDC" or the "Fund") (NYSE:ARDC) announced today the declaration of its distribution for the month of August 2026 of $0.1125 per common share, payable as noted below. The following dates apply to the declared distribution:Ex-Date: August 21, 2026 Record Date: August 21, 2026 Payable Date: August 31, 2026 Per Share Amount: $0.1125Based on the Fund's current share price of $12.48 (as of its close on August 10, 2026), the distribution represents an annualized distribution rate of approximately 10.82% (calculated by annualizing the distribution amount and dividing it by the current price). Information regarding t https://www.quantisnow.com/insight/ares-dynamic-credit-allocation-fund-declares-a-monthly-distribution-of-6675885 https://www.quantisnow.com/insight/ares-dynamic-credit-allocation-fund-declares-a-monthly-distribution-of-6675885 Tue, 11 Aug 2026 20:15:00 GMT 43K voluntary new business policies sold in the quarter, a record for American Integrity, up 54% vs. the second quarter of 2025 and 44% vs. the first quarter of 2026 $46.4 million of income before income taxes, a new quarterly record for American Integrity Gross premiums written grew 14% year-over-year to $327 million during the quarter Successfully renewed 2026-2027 catastrophe excess of loss reinsurance program on June 1, 2026 with a risk-adjusted rate decrease at the upper end of 15-20% declines American Integrity Insurance Group, Inc. ("American Integrity," "we," "us," "our" or the "Company") (NYSE:AII), reported second quarter 2026 results. Robert Ritchie, Chief Executive Off https://www.quantisnow.com/insight/american-integrity-insurance-group-inc-reports-second-quarter-2026-results-6675878 https://www.quantisnow.com/insight/american-integrity-insurance-group-inc-reports-second-quarter-2026-results-6675878 Tue, 11 Aug 2026 20:15:00 GMT Revenue of $20.7 million, up 52.3% year-over-yearGross margin of 21.5%Cash and cash equivalents of $91.1 million as of June 30, 2026New Livermore Production Campus expected to triple manufacturing capacity and support accelerating demandIncreases 2026 revenue guidance to $65 million to $75 million, from $60 million to $70 millionFREMONT, Calif., Aug. 11, 2026 /PRNewswire/ -- Velo3D, Inc. (NASDAQ:VELO) ("Velo3D" or the "Company"), a leader in additive manufacturing ("AM") technology known for transforming aerospace and defense supply chains through world-class metal AM, today announced financial results for its second quarter ended June 30, 2026.   https://www.quantisnow.com/insight/velo3d-announces-second-quarter-2026-financial-results-6675821 https://www.quantisnow.com/insight/velo3d-announces-second-quarter-2026-financial-results-6675821 Tue, 11 Aug 2026 20:05:00 GMT Launch and spacecraft vehicles in assembly at the Rocket Ranch, which supports ramped up capacity of carbon composite tanks and structures. CEDAR PARK, Texas, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Firefly Aerospace (NASDAQ:FLY), a market leading space and defense technology company, today issued financial results for the second quarter ended June 30, 2026. "Breaking the $100 million mark with another quarterly revenue record demonstrates Firefly's amplified growth. With more than a half dozen contract wins during the second quarter, we are matching execution to rocket, spacecraft, and software orders across our programs," said Jason Kim, CEO of Firefly Aerospace. "Firefly is leadi https://www.quantisnow.com/insight/firefly-aerospace-announces-second-quarter-2026-financial-results-with-record-6675792 https://www.quantisnow.com/insight/firefly-aerospace-announces-second-quarter-2026-financial-results-with-record-6675792 Tue, 11 Aug 2026 20:10:00 GMT Record Second Quarter Revenue and Revenue Backlog Highlight Unprecedented Demand for CoreWeave Cloud CoreWeave, Inc. (NASDAQ:CRWV), The Essential Cloud for AI™, today reported financial results for the second quarter ended June 30, 2026. "CoreWeave reached an important inflection point this quarter as our scale began to translate into expanding operating leverage. Customer demand is accelerating, as enterprise adoption broadens and we continue to deepen our technology platform," said Michael Intrator, co-founder, chairman, and chief executive officer of CoreWeave. "CoreWeave is built on the conviction that AI is foundational to every industry and that realizing its full potential requir https://www.quantisnow.com/insight/coreweave-reports-strong-second-quarter-2026-results-6675790 https://www.quantisnow.com/insight/coreweave-reports-strong-second-quarter-2026-results-6675790 Tue, 11 Aug 2026 20:10:00 GMT Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCRC Following successful End-of-Phase 2 meeting with FDA, Company aligned on key elements of registrational trial; plans to initiate study in Q1 2027, subject to securing additional financing Completed $10 million Registered Direct offering, extending cash runway SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced financial results for the second https://www.quantisnow.com/insight/cardiff-oncology-reports-second-quarter-2026-results-and-provides-business-6675789 https://www.quantisnow.com/insight/cardiff-oncology-reports-second-quarter-2026-results-and-provides-business-6675789 Tue, 11 Aug 2026 20:10:00 GMT Accelerating U.S.-Made Sodium-Ion Battery Energy Storage Development with the Bridge™ Modular Sodium-Ion System; Early-Stage Opportunities Approaching $1 Billion Signs Letter of Intent with Juniper Energy for 500+ MWh of Sodium-Ion Energy Storage, Anchored by a Planned 80 MWh California Utility Project Signs Non-Binding Letter of Intent for a Strategic Business Combination with Private Energy Sector Company, Implying an Expected $515 Million Combined Enterprise Value and Premium Market Capitalization Valuation for ESS at Signing of Definitive Agreement Management to Host Webcast and Conference Call Today at 5:00 p.m. ET ESS Tech, Inc. ("ESS," "ESS, Inc." or the "Company") (NYSE:GWH) https://www.quantisnow.com/insight/ess-tech-inc-announces-second-quarter-2026-financial-results-6675669 https://www.quantisnow.com/insight/ess-tech-inc-announces-second-quarter-2026-financial-results-6675669 Tue, 11 Aug 2026 20:05:00 GMT Audience Modeling Revenue Grows 19% as Company Streamlines Legacy Search and Strengthens Capital Position Management to host conference call at 4:15 PM ET, Tuesday, August 11, 2026 LITTLE ROCK, Ark., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Inuvo, Inc. (NYSE:INUV), a leader in artificial intelligence advertising technology, today announced financial results for the second quarter ended June 30, 2026, and provided a business update. Recent Business Highlights Audience Modeling Revenue Growth: Second quarter Audience Modeling revenue grew 19% year over year, driven by recent client wins and increased investment from existing IntentKey customers.Enterprise Sales Momentum: Added five new brand-di https://www.quantisnow.com/insight/inuvo-reports-second-quarter-2026-results-6675646 https://www.quantisnow.com/insight/inuvo-reports-second-quarter-2026-results-6675646 Tue, 11 Aug 2026 20:05:00 GMT Total Revenue Growth of 25.0% Year Over Year in the Second Quarter Same Store Sales Growth of 4.2% Year Over Year in the Second Quarter Opened 10 New Stores in the Second Quarter SCOTTSDALE, Ariz., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Black Rock Coffee Bar, Inc. (NASDAQ:BRCB) ("Black Rock Coffee Bar" or the "Company") today announced financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Highlights Opened 10 new stores during the periodTotal revenue of $63.0 million, up 25.0% compared to the prior year periodSame Store Sales Growth(1) increased 4.2% compared to the prior year periodIncome from operations of $4.1 million compared to $3.3 million in the prior ye https://www.quantisnow.com/insight/black-rock-coffee-bar-inc-reports-second-quarter-2026-results-6675640 https://www.quantisnow.com/insight/black-rock-coffee-bar-inc-reports-second-quarter-2026-results-6675640 Tue, 11 Aug 2026 20:05:00 GMT – PDUFA target date of December 22, 2026 for lorundrostat; commercial preparations on-track for launch upon approval – – Appoints accomplished cardiovascular medicine executive Dr. Terry Ferguson as Chief Medical Officer to lead the Company’s medical and late-stage clinical activities – – Strengthened balance sheet and enhanced the long-term economics of lorundrostat through strategic financing initiatives and the repurchase of the Tanabe royalty obligation – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosteron https://www.quantisnow.com/insight/mineralys-therapeutics-reports-second-quarter-2026-financial-results-and-provides-6675635 https://www.quantisnow.com/insight/mineralys-therapeutics-reports-second-quarter-2026-financial-results-and-provides-6675635 Tue, 11 Aug 2026 20:05:00 GMT